Holen Sie sich die Stockscreener-App
205.40
1.14%
-2.37
Handel nachbörslich:
205.39
-0.01
-0.00%
Schlusskurs vom Vortag:
$207.77
Offen:
$207
24-Stunden-Volumen:
293.21K
Relative Volume:
0.35
Marktkapitalisierung:
$10.76B
Einnahmen:
$708.24M
Nettoeinkommen (Verlust:
$-188.30M
KGV:
-54.93
EPS:
-3.7392
Netto-Cashflow:
$-70.99M
1W Leistung:
-5.03%
1M Leistung:
-14.77%
6M Leistung:
+20.86%
1J Leistung:
+73.32%
1-Tages-Spanne:
$205.09
$208.09
1-Wochen-Bereich:
$205.09
$222.46
52-Wochen-Spanne:
$112.90
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
205.40 | 10.90B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – MUN:19X - TradingView
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Zacks Research Upgrades Axsome Therapeutics (NASDAQ:AXSM) to "Hold" - MarketBeat
Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Eagle Health Investments LP Invests $15.92 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – SWB:19X - TradingView
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years - Sahm
Pallas Capital Advisors LLC Acquires Shares of 40,511 Axsome Therapeutics, Inc. $AXSM - MarketBeat
TimesSquare Capital Management LLC Takes Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
OneDigital Investment Advisors LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Significant 33.58% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316 - Moomoo
Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today - Sahm
AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030 - TradingKey
Axsome Therapeutics (NASDAQ:AXSM) Faces A Crucial Test - Kalkine Media
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306 - webull.com
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating - Moomoo
Mizuho raises Axsome Therapeutics stock price target on Auvelity By Investing.com - Investing.com South Africa
Mizuho raises Axsome Therapeutics stock price target on Auvelity - Investing.com
Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating - marketscreener.com
Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - webull.com
AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242 - webull.com
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues - Yahoo Finance
Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now? - Yahoo Finance
RBC cuts Axsome Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition (AXSM) - Seeking Alpha
Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says - marketscreener.com
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Wells Fargo raises Axsome Therapeutics price target to $256 By Investing.com - Investing.com Australia
RBC cuts Axsome Therapeutics stock price target on model updates - Investing.com
Needham raises Axsome Therapeutics stock price target on drug growth By Investing.com - Investing.com South Africa
AXSM Maintained by Wells Fargo -- Price Target Raised to $256 - GuruFocus
Guggenheim raises Axsome Therapeutics stock price target on sales beat By Investing.com - Investing.com Nigeria
Needham raises Axsome Therapeutics stock price target on drug growth - Investing.com
Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating - marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00 - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
4.95 |
4,660 |
23,067 |
11,889 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Sale |
212.01 |
45,004 |
9,541,298 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Sale |
213.95 |
4,660 |
997,007 |
7,229 |
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):